Skip to main contentSkip to navigationSkip to search

Transaction with shares in Curasight A/S made by managerial employee

September 4, 2022


COPENHAGEN – Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS).  

The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted the 1 September 2022.

The transaction comprises the following managerial employee;

Name Position Aggregated volume Price, DKK
Hanne Damgaard Jensen Chief Development Officer 7.600 97.964
Total 7,600 97.964

Hanne Damgaard Jensen total holdings in Curasight A/S after the purchase of the shares is 35,000 shares.

For further information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.